Environmental influences on moult and movement strategies in southern African waterfowl

Includes abstract.Includes bibliographical references.Waterfowl annual life history events in north-temperate regions are driven primarily by predictable seasonal variations in temperature. In contrast, the spatio-temporal availability of adequate resources to waterfowl in the semi-arid regions of southern Africa is determined by rainfall which is extremely variable in timing and intensity. I studied the environmental influences on flight-feather moult and movement strategies of southern African waterfowl. Six duck species that are fairly common in most parts of South Africa were selected for the study, namely; Egyptian Geese, Alopochen aegyptiaca, Spur-winged Geese, Plectropterus gambensis, South African Shelducks, Tadorna cana, Yellow-billed Ducks, Anas undulata, Red-billed Teals, A. erythrorhyncha and Southern Pochards, Netta erythrophthalma. I chose two study sites to represent the extremes of environmental conditions in southern African, namely Barberspan (summer-rainfall region) and Strandfontein (temperate winter-rainfall region). I investigated the underlying responses of Afrotropical waterfowl to stochastic varying environmental conditions in southern Africa and the life-history strategies they have evolved to cope with this variability. The study also compares and contrasts the life-history strategies of southern hemisphere waterfowl with those of the northern hemisphere

Understanding arid-region waterbird community dynamics during lake dry-downs

The community dynamics of organisms that exhibit multi-scale responses to habitat change are poorly understood. We quantified changes in species diversity and the functional composition of a waterbird community over two iterations of a repeated transition, the annual drying-down of arid-region Lake Ngami, Botswana. We used our data to test three theoretical predictions: simplification of the bird community over time due to a reduction in habitat area and concurrent niche loss; large fluctuations in densities of mobile, opportunistic species; and high variance in predator and prey abundance. Despite temporal variance in species accumulation, we observed no obvious simplification and distinct but consistent groupings of abundance and composition across transitional stages. There were some rapid shifts in functional composition, such as loss of deepwater foragers; winners and losers also occurred within foraging guilds. We conclude that understanding community-level trends during transitional periods will require stronger theoretical frameworks that more effectively integrate unique species traits and functional groups. For conservation managers, our study offers a cautionary tale of the importance of understanding connectivity, trajectories of change, and the potential for large fluctuations in animal communities independent of management actions during periods of ecological transition

Influence of season and other factors on avian Trypanosoma spp. and microfilarial prevalence in the Lowveld, South Africa

To comprehend the effects of emerging infectious diseases on both human and animal health, it is necessary to understand the ecology of pathogens that have wildlife reservoirs. In this study, we determined the prevalence of the parasites Trypanosoma spp. and filarial nematodes in the bloodstream of birds in and around the Kruger National Park, South Africa, partly to test the hypothesis that season influences parasitaemia. Other factors considered were foraging habits, gregariousness or solitariness, and whether location might facilitate contact between birds and parasite vectors. Microscopy was used to screen stained blood smears prepared from 685 captured birds of 87 species. It was found that 3.9% of the birds were infected with filarial nematodes (as reflected by the presence of microfilariae) and 3.1% with Trypanosoma spp. No cases of coinfection with both types of parasite were encountered. Ground-foraging and solitary birds had the highest parasite prevalences compared to other birds. Infections were recorded throughout the year at all six sites. The respective percentages of birds harbouring the two parasite types in the dry season were the same (both 2.3%), whereas microfilariae dominated in the wet season (6.9%) and the prevalence of Trypanosoma spp. then was 1.4%. These findings represent new knowledge concerning avian haemoparasite prevalence in an Afrotropical setting – something that has so far been poorly studied. Significance: • The determination by microscopy of the prevalence of microfilariae of filarial nematodes (3.9%) and Trypanosoma (3.1%) in the peripheral blood of 685 birds of 87 species provides new knowledge on birds in Africa. • Unexpectedly, ground-foraging and solitary birds had the highest parasite prevalences. • The possibility of human infection with these two types of avian parasites is considered

Host associations, biogeography, and phylogenetics of avian malaria in southern African waterfowl

The relevance of spatial variation in the environment and host communities for parasite community composition is poorly documented, creating a need for additional case studies from which general principles can be developed. Avian malaria in southern African waterfowl has not previously been studied. As a first step towards documenting and understanding its biogeography, we used PCR and molecular sequencing techniques to analyse 454 blood samples from Afrotropical ducks from 5 different locations (spread around the subregion) for avian malaria. Fifty-five blood samples were positive for one or more genera of haematozoa. The regional infection rate across all sites and sampling periods was 12·1%. Nine individuals carried dual infections containing multiple haematozoa. Fifteen different cytochrome b haplotypes among 52 positives (3 samples failed to sequence) and 61 total sequences were found. Eleven haplotypes closely matched Plasmodium, whereas 4 were more similar to Haemoproteus. Five distinct haematozoan clades were identified. Haemoproteus parasites appeared to be more host-specific than Plasmodium, which occurred at every sampling location and in every host species examined. Therewere no significant differences in overall parasite prevalence attributable to either site or species, although Plasmodium and Haemoproteus occurrences differed by site-species combination and the borderline significance of our test for betweensite variation (P<0·06) implied that with a larger sample size, differences in parasite prevalence among locations might be detectable. (Résumé d'auteur

Linking avian communities and avian influenza ecology in southern Africa using epidemiological functional groups

The ecology of pathogens, and particularly their emergence in multi-host systems, is complex. New approaches are needed to reduce superficial complexities to a level that still allows scientists to analyse underlying and more fundamental processes. One promising approach for simplification is to use an epidemiological-function classification to describe ecological diversity in a way that relates directly to pathogen dynamics. In this article, we develop and apply the epidemiological functional group (EFG) concept to explore the relationships between wild bird communities and avian influenza virus (AIV) in three ecosystems in southern Africa. Using a two year dataset that combined bird counts and bimonthly sampling for AIV, we allocated each bird species to a set of EFGs that captured two overarching epidemiological functions: the capacity of species to maintain AIV in the system, and their potential to introduce the virus. Comparing AIV prevalence between EFGs suggested that the hypothesis that anseriforms (ducks) and charadriiforms (waders) drive AIV epidemiology cannot entirely explain the high prevalence observed in some EFGs. If anseriforms do play an important role in AIV dynamics in each of the three ecosystems, the role of other species in the local maintenance of AIV cannot be ruled out. The EFG concept thus helped us to identify gaps in knowledge and to highlight understudied bird groups that might play a role in AIV epidemiology. In general, the use of EFGs has potential for generating a range of valuable insights in epidemiology, just as functional group approaches have done in ecology

Independent and combined effects of improved water, sanitation, and hygiene, and improved complementary feeding, on child stunting and anaemia in rural Zimbabwe: a cluster-randomised trial.

BACKGROUND: Child stunting reduces survival and impairs neurodevelopment. We tested the independent and combined effects of improved water, sanitation, and hygiene (WASH), and improved infant and young child feeding (IYCF) on stunting and anaemia in in Zimbabwe. METHODS: We did a cluster-randomised, community-based, 2 × 2 factorial trial in two rural districts in Zimbabwe. Clusters were defined as the catchment area of between one and four village health workers employed by the Zimbabwe Ministry of Health and Child Care. Women were eligible for inclusion if they permanently lived in clusters and were confirmed pregnant. Clusters were randomly assigned (1:1:1:1) to standard of care (52 clusters), IYCF (20 g of a small-quantity lipid-based nutrient supplement per day from age 6 to 18 months plus complementary feeding counselling; 53 clusters), WASH (construction of a ventilated improved pit latrine, provision of two handwashing stations, liquid soap, chlorine, and play space plus hygiene counselling; 53 clusters), or IYCF plus WASH (53 clusters). A constrained randomisation technique was used to achieve balance across the groups for 14 variables related to geography, demography, water access, and community-level sanitation coverage. Masking of participants and fieldworkers was not possible. The primary outcomes were infant length-for-age Z score and haemoglobin concentrations at 18 months of age among children born to mothers who were HIV negative during pregnancy. These outcomes were analysed in the intention-to-treat population. We estimated the effects of the interventions by comparing the two IYCF groups with the two non-IYCF groups and the two WASH groups with the two non-WASH groups, except for outcomes that had an important statistical interaction between the interventions. This trial is registered with ClinicalTrials.gov, number NCT01824940. FINDINGS: Between Nov 22, 2012, and March 27, 2015, 5280 pregnant women were enrolled from 211 clusters. 3686 children born to HIV-negative mothers were assessed at age 18 months (884 in the standard of care group from 52 clusters, 893 in the IYCF group from 53 clusters, 918 in the WASH group from 53 clusters, and 991 in the IYCF plus WASH group from 51 clusters). In the IYCF intervention groups, the mean length-for-age Z score was 0·16 (95% CI 0·08-0·23) higher and the mean haemoglobin concentration was 2·03 g/L (1·28-2·79) higher than those in the non-IYCF intervention groups. The IYCF intervention reduced the number of stunted children from 620 (35%) of 1792 to 514 (27%) of 1879, and the number of children with anaemia from 245 (13·9%) of 1759 to 193 (10·5%) of 1845. The WASH intervention had no effect on either primary outcome. Neither intervention reduced the prevalence of diarrhoea at 12 or 18 months. No trial-related serious adverse events, and only three trial-related adverse events, were reported. INTERPRETATION: Household-level elementary WASH interventions implemented in rural areas in low-income countries are unlikely to reduce stunting or anaemia and might not reduce diarrhoea. Implementation of these WASH interventions in combination with IYCF interventions is unlikely to reduce stunting or anaemia more than implementation of IYCF alone. FUNDING: Bill & Melinda Gates Foundation, UK Department for International Development, Wellcome Trust, Swiss Development Cooperation, UNICEF, and US National Institutes of Health.The SHINE trial is funded by the Bill & Melinda Gates Foundation (OPP1021542 and OPP113707); UK Department for International Development; Wellcome Trust, UK (093768/Z/10/Z, 108065/Z/15/Z and 203905/Z/16/Z); Swiss Agency for Development and Cooperation; US National Institutes of Health (2R01HD060338-06); and UNICEF (PCA-2017-0002)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Birdcall lures improve passerine mist-net captures at a sub-tropical African savanna.

Field research techniques are constantly evolving to meet the needs of the scientific community. There is a growing need for field biology studies to shift towards increasing efficiency and quality of results while simultaneously decreasing cost in both the researcher's time and resources. I tested the efficacy of using multiple recorded birdcall lures (n = 172 species) to improve mist-net captures at a subtropical African savanna setting. Capture success was compared between passive and birdcall enhanced mist-nets during winter and summer seasons. Results suggest that the use of birdcalls does significantly increase the total number of birds caught in both seasons and also increases the diversity of passerine species. Conventional passive mist-nets without an audio lure were initially productive but their capture rate subsequently decreased as sampling days progressed. Birdcall lure enhanced mist-nets had a constant capture output during the summer season. The most responsive birds to audio lures were gregarious species (e.g. Pycnonotus barbatus, Dryoscopus cubla, Prionops plumatus, Phoeniculus purpureus, Turdoides jardineii and Lamprotornis chalybaeus) and the aggressive Dicrurus adsimilis and Acridotheres tristis. I conclude that birdcall lures can be used in summer and winter seasons to improve mist-net captures especially for studies focusing on gregarious and aggressive passerine species in a sub-tropical African savanna setting